Barinthus Biotherapeutics plc (BRNS) Stock Analysis

Barinthus Biotherapeutics plc (BRNS) is a publicly traded company in the HEALTHCARE sector. It trades at $0.68, carries a market capitalization of $27.81M. This page summarizes the public market data, fundamentals, and frequently asked questions for BRNS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Barinthus Biotherapeutics plc currently has a Bullish sentiment score of 0.32.

About Barinthus Biotherapeutics plc

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company based in Harwell, United Kingdom, dedicated to pioneering T cell immunotherapeutics that strengthen the immune response against chronic infectious diseases, autoimmune disorders, and various cancers. With a strong emphasis on innovative research and development, Barinthus seeks to transform the treatment landscape through targeted immunotherapies that address pressing health challenges. As it advances its portfolio of...

GNG Research Analysis

GNG Research scores Barinthus Biotherapeutics plc (BRNS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BRNS.

Frequently Asked Questions

Does BRNS pay dividends?

Barinthus Biotherapeutics plc (BRNS) does not currently pay a regular dividend.

What is BRNS's market cap?

Barinthus Biotherapeutics plc (BRNS) has a market capitalization of $27.81M with a current stock price of $0.68.